SCHEDULE: Xencor Reports 1.5% Stake in Zenas BioPharma
Schedule 13G Filing
Xencor, Inc. has disclosed beneficial ownership of 1,000,000 shares, representing 1.5% of Zenas BioPharma, Inc.'s common stock.
Summary
- Xencor, Inc. has filed a Schedule 13G, indicating a change in beneficial ownership of Zenas BioPharma, Inc. common stock.
- Xencor, Inc. now beneficially owns 1,000,000 shares of Zenas BioPharma, Inc. common stock.
- This ownership stake represents 1.5% of the outstanding common stock of Zenas BioPharma, Inc.
- The percentage is based on 65,176,723 shares outstanding as of July 31, 2026, as reported by Zenas BioPharma on August 13, 2026.
Sentiment
Score: 3
Explanation: StockSavvy.ai views this as a neutral filing, primarily reporting a change in beneficial ownership without significant new financial or strategic information.
Positives
- Disclosure of a significant ownership stake by Xencor, Inc. in Zenas BioPharma, Inc. may indicate investor confidence or strategic interest.
Negatives
- The filing does not provide details on the rationale behind the acquisition of shares or any future intentions, leaving the purpose of the stake unclear.
Risks
- The filing does not explicitly mention any risks associated with this ownership change.
Future Outlook
No forward-looking statements or guidance are provided in this filing.
Management Comments
- Celia Eckert, General Counsel & Corporate Secretary of Xencor, Inc., certified that the information in the statement is true, complete, and correct.
Industry Context
StockSavvy.ai notes that Schedule 13G filings are common for institutional investors and other entities acquiring a significant stake in a public company, often signaling a passive investment or a precursor to more active engagement.
Stakeholder Impact
- Shareholders of Zenas BioPharma, Inc. may see increased market interest or potential shifts in stock price due to the disclosure of a new significant beneficial owner.
Next Steps
- No specific next steps are outlined in this filing.
Key Dates
| Date | Description |
|---|---|
| 2026-07-31 | Date as of which Zenas BioPharma, Inc. reported 65,176,723 shares of common stock outstanding. |
| 2026-08-13 | Date Zenas BioPharma, Inc. filed its Quarterly Report on Form 10-Q. |
| 2026-09-30 | Date of event requiring filing of this statement (change in beneficial ownership). |
| 2026-11-05 | Date of signature for the Schedule 13G filing. |
Keywords
beneficial ownership, Schedule 13G, Xencor, Zenas BioPharma, common stock, investment
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.